REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
马里兰州罗克维尔，2024年5月10日 /PRNewswire/ — REGENXBIO Inc.（纳斯达克股票代码：RGNX）今天宣布将参加以下即将举行的投资者会议：
BofA Securities Health Care Conference 2024
Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m. ET
Location: Las Vegas, NV
美银证券2024年医疗保健会议
炉边聊天： 美国东部时间 2024 年 5 月 15 日星期三下午 2:20
地点： 内华达州拉斯维加斯
Stifel 2024 Tailoring Genes Genetic Medicines Forum
Fireside Chat: Tuesday, May 28, 2024 at 4:10 p.m. ET
Location: Virtual
Stifel 2024 定制基因遗传药物论坛
炉边聊天： 美国东部时间 2024 年 5 月 28 日星期二下午 4:10
地点： 虚拟
A live webcast of the presentation at the BofA conference and fireside chat at the Stifel forum can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
可以在REGENXBIO网站的 “投资者” 栏目中观看美银会议演讲的网络直播和Stifel论坛的炉边谈话。网络直播的存档重播将在演示结束后的大约30天内提供。
ABOUT REGENXBIO Inc.
关于 REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
REGENXBIO是一家领先的临床阶段生物技术公司，致力于通过基因疗法的治疗潜力改善生活。自2009年成立以来，REGENXBIO率先开发了AAV Therapeutics，这是一种创新的基因治疗药物。REGENXBIO 正在推进用于视网膜和罕见疾病的 AAV 疗法产品线，包括与艾伯维合作开发的用于治疗湿性 AMD 和糖尿病视网膜病变的 ABBV-RGX-314、用于治疗杜兴氏的 RGX-202 和用于治疗 MPS II 的 RGX-121。成千上万的患者已经使用REGENXBIO的AAV治疗平台接受了治疗，其中包括诺华针对脊髓性肌萎缩症患儿的ZOLGENSMA。AAV Therapeutics设计为一次性治疗，有可能改变为数百万人提供医疗服务的方式。欲了解更多信息，请访问。
Contacts:
联系人：
Dana Cormack
Corporate Communications
[email protected]
达娜·科马克
企业传播
[电子邮件保护]
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
[email protected]
投资者：
Chris Brinzey，ICR Westwicke
339-970-2843
[电子邮件保护]
SOURCE REGENXBIO Inc.
来源 REGENXBIO Inc.